Market Cap 12.69M
Revenue (ttm) 21,796.00
Net Income (ttm) -2.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 6.33
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 162,600
Avg Vol 376,398
Day's Range N/A - N/A
Shares Out 34.43M
Stochastic %K 55%
Beta 2.80
Analysts Sell
Price Target $25.00

Company Profile

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in t...

Industry: Biotechnology
Sector: Healthcare
Phone: 561 406 6154
Address:
1001 North US Highway 1, Suite 504, Jupiter, United States
Greenspam
Greenspam Apr. 2 at 3:20 PM
$JUNS https://www.youtube.com/watch?v=ApYeDSbr3Tg
1 · Reply
Thenew52
Thenew52 Apr. 2 at 3:40 AM
0 · Reply
Flowjob
Flowjob Apr. 1 at 2:53 PM
$JUNS News due for Parkinson's trial in april
0 · Reply
Greenspam
Greenspam Apr. 1 at 10:59 AM
0 · Reply
Thenew52
Thenew52 Mar. 31 at 11:13 PM
0 · Reply
Wizzard88
Wizzard88 Mar. 30 at 5:07 PM
$JUNS How the hell sentiment is bullish on this ?!!!
0 · Reply
Wizzard88
Wizzard88 Mar. 25 at 8:01 PM
$JUNS Garbage of the year … 💩💩
0 · Reply
movam
movam Mar. 25 at 12:56 PM
$JUNS it did go to 2.29.. not looking good. Sorry longs.
0 · Reply
Wizzard88
Wizzard88 Mar. 23 at 5:34 PM
$JUNS $UFG Are you sure about $JUNS ?!!! 🤣
0 · Reply
Thenew52
Thenew52 Mar. 21 at 11:33 PM
$UFG $JUNS Next week will be interesting
0 · Reply
Latest News on JUNS
Jupiter Neurosciences to Participate in NobleCon21

Dec 2, 2025, 4:15 PM EST - 4 months ago

Jupiter Neurosciences to Participate in NobleCon21


Greenspam
Greenspam Apr. 2 at 3:20 PM
$JUNS https://www.youtube.com/watch?v=ApYeDSbr3Tg
1 · Reply
Thenew52
Thenew52 Apr. 2 at 3:40 AM
0 · Reply
Flowjob
Flowjob Apr. 1 at 2:53 PM
$JUNS News due for Parkinson's trial in april
0 · Reply
Greenspam
Greenspam Apr. 1 at 10:59 AM
0 · Reply
Thenew52
Thenew52 Mar. 31 at 11:13 PM
0 · Reply
Wizzard88
Wizzard88 Mar. 30 at 5:07 PM
$JUNS How the hell sentiment is bullish on this ?!!!
0 · Reply
Wizzard88
Wizzard88 Mar. 25 at 8:01 PM
$JUNS Garbage of the year … 💩💩
0 · Reply
movam
movam Mar. 25 at 12:56 PM
$JUNS it did go to 2.29.. not looking good. Sorry longs.
0 · Reply
Wizzard88
Wizzard88 Mar. 23 at 5:34 PM
$JUNS $UFG Are you sure about $JUNS ?!!! 🤣
0 · Reply
Thenew52
Thenew52 Mar. 21 at 11:33 PM
$UFG $JUNS Next week will be interesting
0 · Reply
Wizzard88
Wizzard88 Mar. 19 at 6:44 PM
$JUNS Don’t be shy! I know you are ending red 🤣🤣
0 · Reply
a_s_a_p_Bevo
a_s_a_p_Bevo Mar. 19 at 5:46 PM
$JUNS AGRZ 👀
0 · Reply
Wizzard88
Wizzard88 Mar. 18 at 2:46 PM
$JUNS There is no single day that I don’t curse this shit!! What’s wrong with this company?!!!
0 · Reply
Wizzard88
Wizzard88 Mar. 16 at 6:13 PM
$JUNS I bet this piece of shit will drop more today !! 🤬
0 · Reply
mountainman5050
mountainman5050 Mar. 15 at 11:52 PM
$JUNS how did I end up here?? ✅💚😂
0 · Reply
movam
movam Mar. 13 at 11:53 PM
$JUNS wtf. Short more?
0 · Reply
Thenew52
Thenew52 Mar. 13 at 3:17 PM
$JUNS $UFG I expect to see a return of at least 20% or 30%, or even more, on each soon. Juns needs to regain Nasdaq's performance and will likely do so, just like a year ago. They might surprise us in their next financial report. UFG is doing well; perhaps they could have a surprise announcement soon, but purely speculatively, I think they could return to 1.25 soon.
0 · Reply
Wizzard88
Wizzard88 Mar. 12 at 6:19 PM
$JUNS I got robbed on this turd 💩
0 · Reply
Smokka12
Smokka12 Mar. 12 at 1:07 PM
$JUNS I know several people that are victims of this scam described in this video , this stock $JUNS was one of the multiple stocks that was used for this scam. I fell for it too https://youtu.be/JHdJEYJ6ucY?si=G2Z9LwlzjZRNEH5K
0 · Reply
B2iDigital
B2iDigital Mar. 10 at 3:04 PM
The B2i Digital team is pleased to announce that Jupiter Neurosciences, Inc. (Nasdaq: $JUNS ), a B2i Digital Featured Company, is participating in the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, on Tuesday, March 11, 2026, at 1:30 PM EDT. The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/otc-life-sciences-virtual-investor-forum For the full B2i Digital profile of Jupiter Neurosciences, please visit: https://b2idigital.com/jupiter-neurosciences-1 Virtual Investor Conferences brings together public companies and a global audience of retail and institutional investors for live executive presentations, Q&A sessions, and on-demand replays. The platform is open to public companies listed on NYSE, Nasdaq, TSX, CSE, ASX, and the OTC Markets. Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on developing therapies for neuroinflammation and central nervous system disorders. The company’s lead clinical program is advancing through a Phase IIa trial in Parkinson’s disease. Jupiter is also commercializing Nugevia, a consumer product built on its patented JOTROL technology platform designed to enhance resveratrol bioavailability. Jupiter’s dual-path strategy combines clinical development with commercial revenue generation. Presenting on behalf of Jupiter Neurosciences will be Christer Rosén, Founder, Chairman and Chief Executive Officer. Mr. Rosén brings a track record of building companies across multiple industries. He previously served as Chairman and CEO of EffRx Pharmaceuticals for 17 years, where he guided the company through FDA and EU approvals of Binosto, a treatment for osteoporosis, providing him with extensive experience across pharmaceutical development, regulatory pathways and global distribution. To register for this presentation, visit: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5271529/jupiter-neurosciences-inc-nasdaq-juns?utm_source=b2i&utm_medium=marketing&utm_campaign=0326LifeSciencesVIC For more information about Jupiter Neurosciences, visit: https://jupiterneurosciences.com/investors/ Content about any specific company was provided and approved by that company or is available in the public domain. B2i Digital, Inc. has not independently verified the accuracy of the information contained herein. The content contained herein is informational only, and no content contained herein shall be considered an offer to solicit the sale of any security or make a recommendation to purchase a security. B2i Digital is not a broker-dealer or investment adviser.
1 · Reply
Wizzard88
Wizzard88 Mar. 10 at 2:43 PM
$JUNS You really think there is a hope for this piece of shit 💩? 🤣🤣
0 · Reply